Citadel Advisors’s Drugs Made In America Acquisition Corp Units DMAAU Stock Holding History

Citadel Advisors’s Portfolio DMAAU Stock Details DMAAU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,964	Closed	-$125K	–	14522
2025 Q3	$125K	Sell	11,964 -2,062	-15%	-$21.6K	﹤0.01%	11675
2025 Q2	$145K	Sell	14,026 -1,727	-11%	-$17.7K	﹤0.01%	10994
2025 Q1	$159K	Buy	+15,753	New	+$159K	﹤0.01%	10782

Other funds holding DMAAU

Kryger Capital London, United Kingdom $1.75B AUM 102.57% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

RCM

Robinson Capital Management Grosse Pointe Farms, Michigan $226M AUM 6.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors's DMAAU Position: Q4 2025 in Review

Citadel Advisors sold out of Drugs Made In America Acquisition Corp Units (DMAAU) in Q4 2025, closing a stake of 11,964 shares — an estimated $125K sold.

Citadel Advisors first reported a position in DMAAU in Q1 2025 and held it in 3 quarters. The position peaked at $159K in Q1 2025. 5 funds tracked by Wall St. Rank hold DMAAU as of Q4 2025.

Citadel Advisors reported no remaining Drugs Made In America Acquisition Corp Units position as of Q4 2025 after selling out during the quarter.
Citadel Advisors sold 11,964 Drugs Made In America Acquisition Corp Units shares in Q4 2025, an estimated $125K.
Citadel Advisors first reported a position in Drugs Made In America Acquisition Corp Units in Q1 2025 and held it in 3 quarters.
Citadel Advisors's Drugs Made In America Acquisition Corp Units position peaked at $159K in Q1 2025.
5 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Units as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.